SG11202003247RA - Rna sequence adaptation - Google Patents

Rna sequence adaptation

Info

Publication number
SG11202003247RA
SG11202003247RA SG11202003247RA SG11202003247RA SG11202003247RA SG 11202003247R A SG11202003247R A SG 11202003247RA SG 11202003247R A SG11202003247R A SG 11202003247RA SG 11202003247R A SG11202003247R A SG 11202003247RA SG 11202003247R A SG11202003247R A SG 11202003247RA
Authority
SG
Singapore
Prior art keywords
rna sequence
sequence adaptation
adaptation
rna
sequence
Prior art date
Application number
SG11202003247RA
Inventor
Stefan Heinz
Tilmann Roos
Dominik Vahrenhorst
Markus Conzelmann
Original Assignee
Curevac Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Curevac Ag filed Critical Curevac Ag
Publication of SG11202003247RA publication Critical patent/SG11202003247RA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/10Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1003Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor
    • C12N15/1006Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor by means of a solid support carrier, e.g. particles, polymers
    • C12N15/101Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor by means of a solid support carrier, e.g. particles, polymers by chromatography, e.g. electrophoresis, ion-exchange, reverse phase
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00Processes for the preparation of sugar derivatives
    • C07H1/06Separation; Purification
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • A61K31/713Double-stranded nucleic acids or oligonucleotides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • A61K39/145Orthomyxoviridae, e.g. influenza virus
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00Preparation of compounds containing saccharide radicals
    • C12P19/26Preparation of nitrogen-containing carbohydrates
    • C12P19/28N-glycosides
    • C12P19/30Nucleotides
    • C12P19/34Polynucleotides, e.g. nucleic acids, oligoribonucleotides
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
SG11202003247RA 2017-11-08 2018-11-08 Rna sequence adaptation SG11202003247RA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP2017078647 2017-11-08
PCT/EP2018/080692 WO2019092153A1 (en) 2017-11-08 2018-11-08 Rna sequence adaptation

Publications (1)

Publication Number Publication Date
SG11202003247RA true SG11202003247RA (en) 2020-05-28

Family

ID=60450603

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202003247RA SG11202003247RA (en) 2017-11-08 2018-11-08 Rna sequence adaptation

Country Status (8)

Country Link
US (1) US11692002B2 (en)
EP (1) EP3707271A1 (en)
JP (1) JP2021502079A (en)
CN (1) CN111511924A (en)
IL (1) IL274442A (en)
RU (1) RU2020117848A (en)
SG (1) SG11202003247RA (en)
WO (1) WO2019092153A1 (en)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201506052PA (en) 2013-02-22 2015-09-29 Curevac Gmbh Combination of vaccination and inhibition of the pd-1 pathway
DE202015009961U1 (en) 2014-12-12 2022-01-25 Curevac Ag Artificial nucleic acid molecules for improved protein expression
EP3294885B1 (en) 2015-05-08 2020-07-01 CureVac Real Estate GmbH Method for producing rna
DK3303583T3 (en) 2015-05-29 2020-07-13 Curevac Real Estate Gmbh METHOD FOR PREPARATION AND PURIFICATION OF RNA, INCLUDING AT LEAST ONE STEP FOR TANGENTIAL FLOW FILTRATION
EP3373965A1 (en) 2015-11-09 2018-09-19 CureVac AG Rotavirus vaccines
WO2017109134A1 (en) 2015-12-22 2017-06-29 Curevac Ag Method for producing rna molecule compositions
EP3423595A1 (en) 2016-03-03 2019-01-09 CureVac AG Rna analysis by total hydrolysis
EP3601576A1 (en) 2017-03-24 2020-02-05 CureVac AG Nucleic acids encoding crispr-associated proteins and uses thereof
MA49922A (en) 2017-08-18 2021-06-02 Modernatx Inc PROCESSES FOR HPLC ANALYSIS
EP3673069A1 (en) 2017-08-22 2020-07-01 CureVac AG Bunyavirales vaccine
RU2020117848A (en) 2017-11-08 2021-12-08 Куревак Аг PHK SEQUENCE ADAPTATION
EP3723796A1 (en) 2017-12-13 2020-10-21 CureVac AG Flavivirus vaccine
WO2019122371A1 (en) 2017-12-21 2019-06-27 Curevac Ag Linear double stranded dna coupled to a single support or a tag and methods for producing said linear double stranded dna
US11576966B2 (en) 2020-02-04 2023-02-14 CureVac SE Coronavirus vaccine
US11241493B2 (en) 2020-02-04 2022-02-08 Curevac Ag Coronavirus vaccine
NL2025475B1 (en) * 2020-04-30 2021-11-09 Ribopro B V Rna molecules with decreased immunogenicity and methods for reducing rna immunogenicity
KR20230053008A (en) 2020-05-29 2023-04-20 큐어백 에스이 Nucleic Acid-Based Combination Vaccines
EP4165205A1 (en) * 2020-06-15 2023-04-19 CureVac SE Analysis of nucleic acid mixtures
WO2022023559A1 (en) 2020-07-31 2022-02-03 Curevac Ag Nucleic acid encoded antibody mixtures
WO2022043551A2 (en) 2020-08-31 2022-03-03 Curevac Ag Multivalent nucleic acid based coronavirus vaccines
CA3205569A1 (en) 2020-12-22 2022-06-30 CureVac SE Rna vaccine against sars-cov-2 variants
EP4313152A1 (en) 2021-03-26 2024-02-07 GlaxoSmithKline Biologicals S.A. Immunogenic compositions
WO2022266389A1 (en) * 2021-06-17 2022-12-22 Modernatx, Inc. Alternative rna purification strategies
WO2024068545A1 (en) 2022-09-26 2024-04-04 Glaxosmithkline Biologicals Sa Influenza virus vaccines

Family Cites Families (145)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6475388B1 (en) 1996-11-13 2002-11-05 Transgenomic, Inc. Method and system for RNA analysis by matched ion polynucleotide chromatography
EP1800697B1 (en) 2001-06-05 2010-04-14 CureVac GmbH Stabilised mRNA with increased G/C-content for use in gene therapy
DE10162480A1 (en) 2001-12-19 2003-08-07 Ingmar Hoerr The application of mRNA for use as a therapeutic agent against tumor diseases
DE10229872A1 (en) 2002-07-03 2004-01-29 Curevac Gmbh Immune stimulation through chemically modified RNA
DE10335833A1 (en) 2003-08-05 2005-03-03 Curevac Gmbh Transfection of blood cells with mRNA for immune stimulation and gene therapy
WO2005116204A1 (en) 2004-05-11 2005-12-08 Rnai Co., Ltd. Polynucleotide causing rna interfere and method of regulating gene expression with the use of the same
DE102004042546A1 (en) 2004-09-02 2006-03-09 Curevac Gmbh Combination therapy for immune stimulation
DE102005023170A1 (en) 2005-05-19 2006-11-23 Curevac Gmbh Optimized formulation for mRNA
JP2009544754A (en) 2006-07-28 2009-12-17 アプライド バイオシステムズ, エルエルシー Dinucleotide MRNA cap analog
DE102006035618A1 (en) 2006-07-31 2008-02-07 Curevac Gmbh New nucleic acid useful as immuno-stimulating adjuvant for manufacture of a composition for treatment of cancer diseases e.g. colon carcinomas and infectious diseases e.g. influenza and malaria
EP2046954A2 (en) 2006-07-31 2009-04-15 Curevac GmbH NUCLEIC ACID OF FORMULA (I): GIXmGn, OR (II): CIXmCn, IN PARTICULAR AS AN IMMUNE-STIMULATING AGENT/ADJUVANT
DE102006061015A1 (en) * 2006-12-22 2008-06-26 Curevac Gmbh Process for the purification of RNA on a preparative scale by HPLC
DE102007001370A1 (en) 2007-01-09 2008-07-10 Curevac Gmbh RNA-encoded antibodies
CA2692906C (en) 2007-06-19 2016-01-19 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Synthesis and use of anti-reverse phosphorothioate analogs of the messenger rna cap
WO2009030254A1 (en) 2007-09-04 2009-03-12 Curevac Gmbh Complexes of rna and cationic peptides for transfection and for immunostimulation
WO2009046738A1 (en) 2007-10-09 2009-04-16 Curevac Gmbh Composition for treating lung cancer, particularly of non-small lung cancers (nsclc)
WO2009046739A1 (en) 2007-10-09 2009-04-16 Curevac Gmbh Composition for treating prostate cancer (pca)
US20110117125A1 (en) 2008-01-02 2011-05-19 Tekmira Pharmaceuticals Corporation Compositions and methods for the delivery of nucleic acids
EP2176408B9 (en) 2008-01-31 2015-11-11 Curevac GmbH NUCLEIC ACIDS COMPRISING FORMULA (NuGiXmGnNv)a AND DERIVATIVES THEREOF AS AN IMMUNOSTIMULATING AGENTS /ADJUVANTS
NZ588583A (en) 2008-04-15 2012-08-31 Protiva Biotherapeutics Inc Novel lipid formulations for nucleic acid delivery
ES2470644T3 (en) 2008-05-26 2014-06-24 Universitt Zrich Protamine / RNA nanoparticles for immunostimulation
PL215513B1 (en) 2008-06-06 2013-12-31 Univ Warszawski New borane phosphate analogs of dinucleotides, their application, RNA particle, method of obtaining RNA and method of obtaining peptides or protein
WO2010037408A1 (en) 2008-09-30 2010-04-08 Curevac Gmbh Composition comprising a complexed (m)rna and a naked mrna for providing or enhancing an immunostimulatory response in a mammal and uses thereof
EP3225621A1 (en) 2008-10-09 2017-10-04 Arbutus Biopharma Corporation Improved amino lipids and methods for the delivery of nucleic acids
WO2010048536A2 (en) 2008-10-23 2010-04-29 Alnylam Pharmaceuticals, Inc. Processes for preparing lipids
CA3039251C (en) 2008-11-10 2024-01-09 Arbutus Biopharma Corporation Novel lipids and compositions for the delivery of therapeutics
AU2010208035B2 (en) 2009-01-29 2016-06-23 Arbutus Biopharma Corporation Improved lipid formulation for the delivery of nucleic acids
CN102421417B (en) 2009-05-05 2016-03-02 阿尔尼拉姆医药品有限公司 Lipid composition
EP2440183B1 (en) 2009-06-10 2018-07-18 Arbutus Biopharma Corporation Improved lipid formulation
EP2281579A1 (en) 2009-08-05 2011-02-09 BioNTech AG Vaccine composition comprising 5'-Cap modified RNA
US20110053829A1 (en) 2009-09-03 2011-03-03 Curevac Gmbh Disulfide-linked polyethyleneglycol/peptide conjugates for the transfection of nucleic acids
WO2011069529A1 (en) 2009-12-09 2011-06-16 Curevac Gmbh Mannose-containing solution for lyophilization, transfection and/or injection of nucleic acids
JP5893611B2 (en) 2010-06-03 2016-03-23 アルニラム・ファーマシューティカルズ・インコーポレーテッド Biodegradable lipids for delivery of active agents
ES2558106T3 (en) 2010-07-30 2016-02-02 Curevac Ag Formation of nucleic acid complexes with disulfide-cross-linked cationic components for transfection and immunostimulation
WO2012019630A1 (en) 2010-08-13 2012-02-16 Curevac Gmbh Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded protein
WO2012089225A1 (en) 2010-12-29 2012-07-05 Curevac Gmbh Combination of vaccination and inhibition of mhc class i restricted antigen presentation
WO2012116715A1 (en) 2011-03-02 2012-09-07 Curevac Gmbh Vaccination in newborns and infants
WO2012113413A1 (en) 2011-02-21 2012-08-30 Curevac Gmbh Vaccine composition comprising complexed immunostimulatory nucleic acids and antigens packaged with disulfide-linked polyethyleneglycol/peptide conjugates
WO2012116714A1 (en) 2011-03-02 2012-09-07 Curevac Gmbh Vaccination in elderly patients
US8969545B2 (en) 2011-10-18 2015-03-03 Life Technologies Corporation Alkynyl-derivatized cap analogs, preparation and uses thereof
WO2013113326A1 (en) 2012-01-31 2013-08-08 Curevac Gmbh Pharmaceutical composition comprising a polymeric carrier cargo complex and at least one protein or peptide antigen
EP2623121A1 (en) 2012-01-31 2013-08-07 Bayer Innovation GmbH Pharmaceutical composition comprising a polymeric carrier cargo complex and an antigen
WO2013113325A1 (en) 2012-01-31 2013-08-08 Curevac Gmbh Negatively charged nucleic acid comprising complexes for immunostimulation
WO2013120497A1 (en) 2012-02-15 2013-08-22 Curevac Gmbh Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein
WO2013120498A1 (en) 2012-02-15 2013-08-22 Curevac Gmbh Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded allergenic antigen or an autoimmune self-antigen
WO2013120500A1 (en) 2012-02-15 2013-08-22 Curevac Gmbh Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded tumour antigen
WO2013120499A1 (en) 2012-02-15 2013-08-22 Curevac Gmbh Nucleic acid comprising or coding for a histone stem-loop and a poly (a) sequence or a polyadenylation signal for increasing the expression of an encoded pathogenic antigen
US9890391B2 (en) 2012-03-27 2018-02-13 Curevac Ag RNA vector with an open reading frame, an albumin 3′-UTR, and a histone stem loop
CA2866945C (en) 2012-03-27 2021-05-04 Curevac Gmbh Artificial nucleic acid molecules comprising a 5'top utr
ES2654205T3 (en) 2012-03-27 2018-02-12 Curevac Ag Artificial nucleic acid molecules for enhanced protein or peptide expression
EP2854857B1 (en) 2012-05-25 2018-11-28 CureVac AG Reversible immobilization and/or controlled release of nucleic acid containing nanoparticles by (biodegradable) polymer coatings
SG11201506052PA (en) 2013-02-22 2015-09-29 Curevac Gmbh Combination of vaccination and inhibition of the pd-1 pathway
ES2702466T3 (en) 2013-08-21 2019-03-01 Curevac Ag Procedure to increase the expression of proteins encoded by RNA
CN105530952A (en) 2013-08-21 2016-04-27 库瑞瓦格股份公司 Composition and vaccine for treating lung cancer
WO2015024669A1 (en) 2013-08-21 2015-02-26 Curevac Gmbh Combination vaccine
SG10201801431TA (en) 2013-08-21 2018-04-27 Curevac Ag Respiratory syncytial virus (rsv) vaccine
BR112016000889A2 (en) 2013-08-21 2017-12-12 Curevac Ag composition and vaccine for prostate cancer treatment
CA2915712A1 (en) 2013-08-21 2015-02-26 Margit SCHNEE Rabies vaccine
ES2806575T3 (en) 2013-11-01 2021-02-18 Curevac Ag Modified RNA with decreased immunostimulatory properties
SG10201805660WA (en) 2013-12-30 2018-08-30 Curevac Ag Methods for rna analysis
RU2717986C2 (en) 2013-12-30 2020-03-27 Куревак Аг Artificial molecules of nucleic acid
JP6584414B2 (en) 2013-12-30 2019-10-02 キュアバック アーゲー Artificial nucleic acid molecule
ES2754239T3 (en) 2014-03-12 2020-04-16 Curevac Ag Combination of vaccination and OX40 agonists
CA2936286A1 (en) 2014-04-01 2015-10-08 Curevac Ag Polymeric carrier cargo complex for use as an immunostimulating agent or as an adjuvant
RU2595374C2 (en) 2014-04-09 2016-08-27 Федеральное Государственное Бюджетное Учреждение Науки Институт Молекулярной Биологии Им. В.А. Энгельгардта Российской Академии Наук (Имб Ран) Method for automated extraction with simultaneous purification of nucleic acids from several biological samples
PT3155129T (en) 2014-06-10 2019-05-16 Curevac Ag Methods and means for enhancing rna production
DE202015009961U1 (en) 2014-12-12 2022-01-25 Curevac Ag Artificial nucleic acid molecules for improved protein expression
CA2962849A1 (en) 2014-12-16 2016-06-23 Curevac Ag Ebolavirus and marburgvirus vaccines
SG11201704681QA (en) 2014-12-30 2017-07-28 Curevac Ag Artificial nucleic acid molecules
WO2016165825A1 (en) 2015-04-13 2016-10-20 Curevac Ag Method for producing rna compositions
EP4026568A1 (en) 2015-04-17 2022-07-13 CureVac Real Estate GmbH Lyophilization of rna
CA2975333A1 (en) 2015-04-22 2016-10-27 Curevac Ag Rna containing composition for treatment of tumor diseases
EP3289101B1 (en) 2015-04-30 2021-06-23 CureVac AG Immobilized poly(n)polymerase
CN108064307A (en) 2015-04-30 2018-05-22 库瑞瓦格股份公司 The method for carrying out in-vitro transcription using the restriction enzyme of immobilization
EP3294885B1 (en) 2015-05-08 2020-07-01 CureVac Real Estate GmbH Method for producing rna
EP3294326B1 (en) 2015-05-15 2021-04-21 CureVac AG Prime-boost regimens involving administration of at least one mrna construct
EP3298142B1 (en) 2015-05-20 2021-07-14 CureVac AG Dry powder composition comprising long-chain rna
SG11201708541QA (en) 2015-05-20 2017-12-28 Curevac Ag Dry powder composition comprising long-chain rna
US11608513B2 (en) 2015-05-29 2023-03-21 CureVac SE Method for adding cap structures to RNA using immobilized enzymes
DK3303583T3 (en) 2015-05-29 2020-07-13 Curevac Real Estate Gmbh METHOD FOR PREPARATION AND PURIFICATION OF RNA, INCLUDING AT LEAST ONE STEP FOR TANGENTIAL FLOW FILTRATION
WO2016203025A1 (en) 2015-06-17 2016-12-22 Curevac Ag Vaccine composition
WO2017001058A1 (en) 2015-07-01 2017-01-05 Curevac Ag Method for analysis of an rna molecule
US10501768B2 (en) 2015-07-13 2019-12-10 Curevac Ag Method of producing RNA from circular DNA and corresponding template DNA
US20200085852A1 (en) 2015-08-05 2020-03-19 Curevac Ag Epidermal mrna vaccine
EP3332019B1 (en) 2015-08-07 2019-12-18 CureVac AG Process for the in vivo production of rna in a host cell
DE22195354T1 (en) 2015-08-10 2023-05-25 CureVac Manufacturing GmbH METHOD OF INCREASING REPLICATION OF A CIRCULAR DNA MOLECULE
BR112018001995A2 (en) 2015-08-28 2018-09-18 Curevac Ag artificial nucleic acid molecules
US11225682B2 (en) 2015-10-12 2022-01-18 Curevac Ag Automated method for isolation, selection and/or detection of microorganisms or cells comprised in a solution
WO2017066782A1 (en) 2015-10-16 2017-04-20 Modernatx, Inc. Hydrophobic mrna cap analogs
WO2017066791A1 (en) 2015-10-16 2017-04-20 Modernatx, Inc. Sugar substituted mrna cap analogs
AU2016340183A1 (en) 2015-10-16 2018-04-19 Modernatx, Inc. mRNA cap analogs and methods of mRNA capping
SI3362461T1 (en) 2015-10-16 2022-05-31 Modernatx, Inc. Mrna cap analogs with modified phosphate linkage
US11866754B2 (en) 2015-10-16 2024-01-09 Modernatx, Inc. Trinucleotide mRNA cap analogs
WO2017066789A1 (en) 2015-10-16 2017-04-20 Modernatx, Inc. Mrna cap analogs with modified sugar
EP3373965A1 (en) 2015-11-09 2018-09-19 CureVac AG Rotavirus vaccines
US20180312545A1 (en) 2015-11-09 2018-11-01 Curevac Ag Optimized nucleic acid molecules
EP3394237A1 (en) 2015-12-21 2018-10-31 CureVac AG Inlay for a culture plate and corresponding method for preparing a culture plate system with such inlay
WO2017109134A1 (en) 2015-12-22 2017-06-29 Curevac Ag Method for producing rna molecule compositions
WO2017109161A1 (en) 2015-12-23 2017-06-29 Curevac Ag Method of rna in vitro transcription using a buffer containing a dicarboxylic acid or tricarboxylic acid or a salt thereof
EP3414340B1 (en) 2016-02-12 2023-08-09 CureVac SE Method for analyzing rna
US20190049414A1 (en) 2016-02-15 2019-02-14 Curevac Ag Method for analyzing by-products of rna in vitro transcription
SG10201913630YA (en) 2016-02-17 2020-03-30 Curevac Ag Zika virus vaccine
EP3423595A1 (en) 2016-03-03 2019-01-09 CureVac AG Rna analysis by total hydrolysis
US20190177714A1 (en) 2016-03-24 2019-06-13 Curevac Ag Immobilized inorganic pyrophosphatase (ppase)
WO2017182634A1 (en) 2016-04-22 2017-10-26 Curevac Ag Rna encoding a tumor antigen
US11596699B2 (en) 2016-04-29 2023-03-07 CureVac SE RNA encoding an antibody
US20180126003A1 (en) 2016-05-04 2018-05-10 Curevac Ag New targets for rna therapeutics
EP3452101A2 (en) 2016-05-04 2019-03-13 CureVac AG Rna encoding a therapeutic protein
WO2017191264A1 (en) 2016-05-04 2017-11-09 Curevac Ag Nucleic acid molecules and uses thereof
EP4233898A3 (en) 2016-05-04 2023-11-01 CureVac SE Influenza mrna vaccines
WO2017203008A1 (en) 2016-05-25 2017-11-30 Curevac Ag Novel biomarkers
EP3468608A1 (en) 2016-06-09 2019-04-17 CureVac AG Hybrid carriers for nucleic acid cargo
US20190336608A1 (en) 2016-06-09 2019-11-07 Curevac Ag Cationic carriers for nucleic acid delivery
EP3468612A1 (en) 2016-06-09 2019-04-17 CureVac AG Hybrid carriers for nucleic acid cargo
US11478552B2 (en) 2016-06-09 2022-10-25 Curevac Ag Hybrid carriers for nucleic acid cargo
CN106442827B (en) * 2016-07-18 2018-01-19 北京工业大学 It is a kind of using fluid dynamic chromatogram simultaneously the multigroup microRNA of separation detection method
CN109715205A (en) 2016-08-19 2019-05-03 库瑞瓦格股份公司 RNA use for cancer treatment
CN110352071A (en) 2016-10-26 2019-10-18 库瑞瓦格股份公司 Lipidic nanoparticles mRNA vaccine
WO2018096179A1 (en) 2016-11-28 2018-05-31 Curevac Ag Method for purifying rna
EP3808380A1 (en) 2016-12-08 2021-04-21 CureVac AG Rna for treatment or prophylaxis of a liver disease
WO2018104540A1 (en) 2016-12-08 2018-06-14 Curevac Ag Rnas for wound healing
WO2018115525A1 (en) 2016-12-23 2018-06-28 Curevac Ag Lassa virus vaccine
WO2018115507A2 (en) 2016-12-23 2018-06-28 Curevac Ag Henipavirus vaccine
US11141476B2 (en) 2016-12-23 2021-10-12 Curevac Ag MERS coronavirus vaccine
EP3595715A1 (en) 2017-03-17 2020-01-22 CureVac AG Rna vaccine and immune checkpoint inhibitors for combined anticancer therapy
EP3601576A1 (en) 2017-03-24 2020-02-05 CureVac AG Nucleic acids encoding crispr-associated proteins and uses thereof
US20230064106A1 (en) 2017-05-17 2023-03-02 Curevac Real Estate Gmbh Method for determining at least one quality parameter of an rna sample
EP3648791A1 (en) 2017-07-04 2020-05-13 CureVac AG Novel nucleic acid molecules
EP3673069A1 (en) 2017-08-22 2020-07-01 CureVac AG Bunyavirales vaccine
KR20200071081A (en) 2017-10-19 2020-06-18 큐어백 아게 New artificial nucleic acid molecule
RU2020117848A (en) 2017-11-08 2021-12-08 Куревак Аг PHK SEQUENCE ADAPTATION
EP3723796A1 (en) 2017-12-13 2020-10-21 CureVac AG Flavivirus vaccine
WO2019122371A1 (en) 2017-12-21 2019-06-27 Curevac Ag Linear double stranded dna coupled to a single support or a tag and methods for producing said linear double stranded dna
US20210361761A1 (en) 2018-04-05 2021-11-25 Curevac Ag Novel yellow fever nucleic acid molecules for vaccination
JP2021519595A (en) 2018-04-17 2021-08-12 キュアバック アーゲー New RSV RNA molecule and vaccination composition
WO2020002525A1 (en) 2018-06-27 2020-01-02 Curevac Ag Novel lassa virus rna molecules and compositions for vaccination
MX2020013148A (en) 2018-06-28 2021-03-02 CureVac RNA Printer GmbH Bioreactor for rna in vitro transcription.
TW202039534A (en) 2018-12-14 2020-11-01 美商美國禮來大藥廠 Kras variant mrna molecules
CA3122645A1 (en) 2018-12-21 2020-06-25 Curevac Ag Methods for rna analysis
US20220040281A1 (en) 2018-12-21 2022-02-10 Curevac Ag Rna for malaria vaccines
CA3125511A1 (en) 2019-02-08 2020-08-13 Curevac Ag Coding rna administered into the suprachoroidal space in the treatment of ophthalmic diseases
US20220313813A1 (en) 2019-06-18 2022-10-06 Curevac Ag Rotavirus mrna vaccine
BR112022001947A2 (en) 2019-08-14 2022-09-20 Curevac Ag RNA COMBINATIONS AND COMPOSITIONS WITH REDUCED IMMUNOSTIMULATORY PROPERTIES
US11241493B2 (en) 2020-02-04 2022-02-08 Curevac Ag Coronavirus vaccine
KR20230053008A (en) 2020-05-29 2023-04-20 큐어백 에스이 Nucleic Acid-Based Combination Vaccines

Also Published As

Publication number Publication date
JP2021502079A (en) 2021-01-28
US11692002B2 (en) 2023-07-04
CN111511924A (en) 2020-08-07
US20220144877A1 (en) 2022-05-12
RU2020117848A (en) 2021-12-08
EP3707271A1 (en) 2020-09-16
IL274442A (en) 2020-06-30
WO2019092153A1 (en) 2019-05-16

Similar Documents

Publication Publication Date Title
IL274442A (en) Rna sequence adaptation
ZA201905396B (en) Trans-replicating rna
GB201806688D0 (en) No details
GB201803663D0 (en) No details
GB201801258D0 (en) No details
GB201812685D0 (en) No details
GB201721011D0 (en) No details
IL277921A (en) Novel small activating rna
GB201801628D0 (en) No details
EP3684343C0 (en) Improved supraparticles
GB201807647D0 (en) No details
IL272526A (en) Improved endoinulinases
GB201710451D0 (en) Comford aid
GB201717719D0 (en) No details
GB201811353D0 (en) No details
GB201802344D0 (en) No details
GB201720890D0 (en) No details
GB201801239D0 (en) No details
GB201709043D0 (en) No details
GB201811817D0 (en) No details
GB201718538D0 (en) u
GB201707210D0 (en) Improved hitchlock
GB201811897D0 (en) No details
GB201722151D0 (en) No details
GB201722063D0 (en) No details